{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:46:09Z","timestamp":1773337569368,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203933"],"award-info":[{"award-number":["82203933"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special Program of National Natural Science Foundation of China","award":["32141004"],"award-info":[{"award-number":["32141004"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-059"],"award-info":[{"award-number":["2021-I2M-1-059"]}]},{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2020-RC320-003"],"award-info":[{"award-number":["2020-RC320-003"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3601800"],"award-info":[{"award-number":["2022YFC3601800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02995-5","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:52:14Z","timestamp":1756169534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relative sensitivity and preference of indicators in pharmaceutical trials of psoriasis and psoriatic arthritis"],"prefix":"10.1186","volume":"30","author":[{"given":"Shuntong","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingru","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"issue":"9997","key":"2995_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet (London, England). 2015;386(9997):983\u201394.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"2995_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59.","journal-title":"Nat Rev Dis Primers"},{"issue":"10275","key":"2995_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerb\u00e4ck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet (London, England). 2021;397(10275):754\u201366.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"2995_CR4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/jid.2009.391","volume":"130","author":"PI Spuls","year":"2010","unstructured":"Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933\u201343.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2995_CR5","doi-asserted-by":"publisher","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","volume":"64","author":"SR Feldman","year":"2005","unstructured":"Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(2):ii65\u20138 (discussion ii9-73).","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2995_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica. 1978;157(4):238\u201344.","journal-title":"Dermatologica"},{"issue":"3","key":"2995_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/art.40391","volume":"70","author":"LC Coates","year":"2018","unstructured":"Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, et al. Group for research and assessment of psoriasis and psoriatic arthritis\/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthr Rheumatol (Hoboken, NJ). 2018;70(3):345\u201355.","journal-title":"Arthr Rheumatol (Hoboken, NJ)"},{"issue":"3","key":"2995_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","volume":"55","author":"A McArdle","year":"2018","unstructured":"McArdle A, Pennington S, FitzGerald O. Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs. Clin Rev Allergy Immunol. 2018;55(3):271\u201394.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"2995_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7): e1000100.","journal-title":"PLoS Med"},{"key":"2995_CR10","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed). 2019;366: l4898.","journal-title":"BMJ (Clin Res Ed)"},{"key":"2995_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-000942","author":"J Tian","year":"2023","unstructured":"Tian J, Kang S, Zhang D, Huang Y, Yao X, Zhao M, et al. Selection of indicators reporting response rate in pharmaceutical trials for systemic lupus erythematosus: preference and relative sensitivity. Lupus Sci Med. 2023. https:\/\/doi.org\/10.1136\/lupus-2023-000942.","journal-title":"Lupus Sci Med"},{"key":"2995_CR12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.42421","volume":"75","author":"JR Tian","year":"2023","unstructured":"Tian JR, Kang ST, Zhang DY, Lu QJ. Preference and relative sensitivity of indicators reporting response rate in pharmaceutical trials of psoriasis and psoriatic arthritis. Arthritis Rheumatol. 2023;75:937\u201340.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2995_CR13","first-page":"18","volume":"29","author":"MF Mariel","year":"2014","unstructured":"Mariel MF, Christopher JP, Goodarz D, Majid E. Bayesian estimation of population-level trends in measures of health status. Stat Sci. 2014;29(1):18\u201325.","journal-title":"Stat Sci"},{"issue":"3","key":"2995_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/oxfordjournals.aje.a117428","volume":"141","author":"L Joseph","year":"1995","unstructured":"Joseph L, Gyorkos TW, Coupal L. Bayesian estimation of disease prevalence and the parameters of diagnostic tests in the absence of a gold standard. Am J Epidemiol. 1995;141(3):263\u201372.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2995_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1186\/s12889-020-09177-4","volume":"20","author":"M Flor","year":"2020","unstructured":"Flor M, Wei\u00df M, Selhorst T, M\u00fcller-Graf C, Greiner M. Comparison of Bayesian and frequentist methods for prevalence estimation under misclassification. BMC Public Health. 2020;20(1):1135.","journal-title":"BMC Public Health"},{"issue":"10","key":"2995_CR16","doi-asserted-by":"publisher","first-page":"e1320","DOI":"10.4088\/JCP.15f10377","volume":"76","author":"C Andrade","year":"2015","unstructured":"Andrade C. The primary outcome measure and its importance in clinical trials. J Clin Psychiatry. 2015;76(10):e1320\u20133.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"2995_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMra1601511","volume":"375","author":"SJ Pocock","year":"2016","unstructured":"Pocock SJ, Stone GW. The primary outcome is positive\u2014is that good enough? N Engl J Med. 2016;375(10):971\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"2995_CR18","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1046\/j.1523-1747.2003.12145.x","volume":"120","author":"L Naldi","year":"2003","unstructured":"Naldi L, Svensson A, Diepgen T, Elsner P, Grob JJ, Coenraads PJ, et al. Randomized clinical trials for psoriasis 1977\u20132000: the EDEN survey. J Invest Dermatol. 2003;120(5):738\u201341.","journal-title":"J Invest Dermatol"},{"issue":"Suppl 2","key":"2995_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","volume":"24","author":"E Puzenat","year":"2010","unstructured":"Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):10\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2995_CR20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1056\/NEJM200107263450403","volume":"345","author":"CN Ellis","year":"2001","unstructured":"Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345(4):248\u201355.","journal-title":"N Engl J Med"},{"issue":"5","key":"2995_CR21","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1046\/j.1365-2133.2002.04743.x","volume":"146","author":"M Bhushan","year":"2002","unstructured":"Bhushan M, Bleiker TO, Ballsdon AE, Allen MH, Sopwith M, Robinson MK, et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol. 2002;146(5):824\u201331.","journal-title":"Br J Dermatol"},{"issue":"6","key":"2995_CR22","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","volume":"50","author":"CS Carlin","year":"2004","unstructured":"Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859\u201366.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2995_CR23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/bjd.18361","volume":"182","author":"JM Norlin","year":"2020","unstructured":"Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M. Complete skin clearance and Psoriasis area and severity index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. Br J Dermatol. 2020;182(4):965\u201373.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2995_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jdv.12817","volume":"29","author":"L Puig","year":"2015","unstructured":"Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2995_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ad.2014.10.001","volume":"106","author":"T Torres","year":"2015","unstructured":"Torres T, Puig L. Treatment goals for psoriasis: should PASI 90 become the standard of care? Actas Dermo Sifiliogr. 2015;106(3):155\u20137.","journal-title":"Actas Dermo Sifiliogr"},{"issue":"3","key":"2995_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","volume":"66","author":"A Robinson","year":"2012","unstructured":"Robinson A, Kardos M, Kimball AB. Physician global assessment (PGA) and Psoriasis area and severity index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66(3):369\u201375.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2995_CR27","first-page":"1151","volume":"11","author":"N Kirsten","year":"2021","unstructured":"Kirsten N, Rustenbach S, von Kiedrowski R, Sorbe C, Reich K, Augustin M. Which PASI outcome is most relevant to the patients in real-world care? Life (Basel, Switzerland). 2021;11(11):1151.","journal-title":"Life (Basel, Switzerland)."},{"issue":"5","key":"2995_CR28","first-page":"1167","volume":"34","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007;34(5):1167\u201370.","journal-title":"J Rheumatol"},{"issue":"Suppl 11","key":"2995_CR29","first-page":"S64","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Measures of psoriatic arthritis: Tender and swollen joint assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 2011;63(Suppl 11):S64-85.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"2995_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40744-018-0120-8","volume":"5","author":"K de Vlam","year":"2018","unstructured":"de Vlam K, Merola JF, Birt JA, Sandoval DM, Lobosco S, Moon R, et al. Skin involvement in psoriatic arthritis worsens overall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational, cross-sectional study. Rheumatol Ther. 2018;5(2):423\u201336.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"2995_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/247553031016a00403","volume":"16","author":"K Busse","year":"2010","unstructured":"Busse K, Liao W. Which psoriasis patients develop psoriatic arthritis? Psoriasis Forum. 2010;16(4):17\u201325.","journal-title":"Psoriasis Forum"},{"issue":"3","key":"2995_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40744-020-00221-8","volume":"7","author":"W Tillett","year":"2020","unstructured":"Tillett W, Merola JF, Tha\u00e7i D, Holdsworth E, Booth N, Lobosco LS, et al. Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey. Rheumatol Ther. 2020;7(3):617\u201337.","journal-title":"Rheumatol Ther"},{"issue":"10136","key":"2995_CR33","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","volume":"391","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet (London, England). 2018;391(10136):2213\u201324.","journal-title":"Lancet (London, England)"},{"issue":"10222","key":"2995_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","volume":"395","author":"CT Ritchlin","year":"2020","unstructured":"Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet (London, England). 2020;395(10222):427\u201340.","journal-title":"Lancet (London, England)"},{"issue":"10230","key":"2995_CR35","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2020;395(10230):1126\u201336.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"2995_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/annrheumdis-2017-211998","volume":"77","author":"LJJ van Mens","year":"2018","unstructured":"van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis. 2018;77(2):251\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2995_CR37","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrrheum.2011.125","volume":"7","author":"CA Chang","year":"2011","unstructured":"Chang CA, Gottlieb AB, Lizzul PF. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol. 2011;7(10):588\u201398.","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 2","key":"2995_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/annrheumdis-2012-203037","volume":"72","author":"F Villanova","year":"2013","unstructured":"Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013;72(Suppl 2):104\u201310.","journal-title":"Ann Rheum Dis"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02995-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02995-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02995-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:58:32Z","timestamp":1757458712000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02995-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2995"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02995-5","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not applicable, since this research was based exclusively on previously published studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval status"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"803"}}